Welcome to Paid Research Studies




  • Conditions:   Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML);   MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable);   Hematopoietic Stem Cell Transplant
    Interventions:   Drug: Venetoclax;   Drug: Fludarabine;   Drug: Busulfan
    Sponsor:   Jacqueline Garcia, MD
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cladribine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Gemcitabine Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anemia;   ASXL1 Gene Mutation;   EZH2 Gene Mutation;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Plasma Cell Myeloma;   Primary Myelofibrosis;   Recurrent Plasma Cell Myeloma;   Secondary Myelofibrosis;   Thrombocytopenia
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG;   Radiation: Total Marrow Irradiation;   Procedure: Stem Cell Product Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Panobinostat;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Immunodeficiency;   Myelodysplastic Syndrome
    Intervention:  
    Sponsors:   Fred Hutchinson Cancer Research Center;   University of Washington;   Seattle Children's Hospital
    Recruiting

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Sirolimus;   Radiation: Total Body Irradiation;   Biological: Allogeneic peripheral blood stem cell
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting

  • Conditions:   Leukemia, Lymphoid;   Leukemia, Myeloid;   Myelodysplastic Syndromes;   Myelofibrosis;   Lymphoma, Malignant;   Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Biological: Rabbit ATG;   Drug: Methotrexate
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Minimal Residual Disease Negativity
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cutaneous T-cell Lymphoma;   T-Prolymphocytic Leukemia;   T-Large Granulocytic Leukemia;   T-Lymphoblastic Leukemia/Lymphoma;   Peripheral T-Cell Lymphoma
    Interventions:   Drug: Romidepsin;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplant;   Drug: Thymoglobulin
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Celgene Corporation
    Recruiting

  • Conditions:   Fanconi Anemia;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Anti-Thymocyte Globulin (Rabbit);   Device: The CliniMACS device;   Drug: G-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pediatric Brain Tumor Consortium
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   X-Linked Combined Immunodeficiency Diseases
    Interventions:   Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT;   Drug: Palifermin;   Drug: Busulfan
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
    Interventions:   Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Beta Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
    Sponsor:   Columbia University
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Biological: Plerixafor;   Drug: Busulfan;   Genetic: BIVV003
    Sponsor:   Bioverativ - a sanofi company
    Recruiting

  • Conditions:   Severe Combined Immunodeficiency, X Linked;   Gene Therapy
    Intervention:   Biological: autologous CD34+ cell transduced with G2SCID vector
    Sponsors:   David Williams;   University of California, Los Angeles
    Recruiting

  • Conditions:   Hematologic Disorders;   Hemoglobinopathies;   Immunodeficiencies
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Radiation: Total body irradiation;   Biological: Stem cell transplant;   Drug: Keppra
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
    Interventions:   Drug: RIC: Distal Campath;   Drug: RIC:Intermediate Campath;   Drug: RIC: Mini Busulfan
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Severe Combined Immunodeficiency Disease, X-linked
    Interventions:   Genetic: CL20-i4-EF1α-hγc-OPT;   Drug: Busulfan;   Device: CliniMacs
    Sponsors:   St. Jude Children's Research Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Assisi Foundation;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Hematopoietic Stem Cell Transplant (HSCT)
    Interventions:   Drug: Reduced-Intensity Conditioning Regimen;   Drug: Myeloablative Conditioning Regimen
    Sponsor:   Randy Windreich
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting

  • Condition:   X-Linked Chronic Granulomatious Disease
    Interventions:   Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Inherited Immune Deficiencies
    Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Thalassemia;   Sickle Cell Disease;   Diamond Blackfan Anemia;   Acquired Neutropenia in Newborn;   Acquired Anemia Hemolytic;   Acquired Thrombocytopenia;   Hemophagocytic Lymphohistiocytoses;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Common Variable Immunodeficiency;   X-linked Lymphoproliferative Disease;   Severe Combined Immunodeficiency;   Hurler Syndrome;   Mannosidosis;   Adrenoleukodystrophy
    Interventions:   Drug: Thiotepa--single daily dose;   Drug: Thiotepa--escalated dose
    Sponsors:   University of Florida;   Live Like Bella Pediatric Cancer Research
    Recruiting

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Severe Combined Immunodeficiency
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Busulfan;   Drug: Fludarabine;   Drug: Thiotepa;   Device: CliniMACS;   Other: Donor Lymphocyte Infusion
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematologic Neoplasms
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Acute Lymphoblastic Leukemia;   Mixed Lineage Leukemia;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   Juvenile Myelomonocytic Leukemia
    Intervention:   Device: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Erythroid Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Blasts Under 20 Percent of Peripheral Blood White Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Aldesleukin;   Biological: Allogeneic CD56-positive CD3-negative Natural Killer Cells;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   SCID
    Interventions:   Drug: Busulfan;   Device: Cell processing for TCRαβ+/CD19+ depletion
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Cerebral Adrenoleukodystrophy (CALD)
    Intervention:   Drug: Genetic
    Sponsor:   bluebird bio
    Recruiting

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   Locally Advanced Malignant Neoplasm;   NY-ESO-1 Positive;   Unresectable Malignant Neoplasm
    Interventions:   Other: 18F-FHBG;   Biological: Aldesleukin;   Drug: Busulfan;   Biological: Cellular Therapy;   Procedure: Computed Tomography;   Biological: Filgrastim;   Drug: Fludarabine;   Procedure: Leukapheresis;   Drug: Plerixafor;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute for Regenerative Medicine (CIRM);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
    Interventions:   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis;   Drug: Anti-seizure prophylaxis;   Drug: Ursodiol
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Diagnostic Test: NGS-MRD;   Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
    Sponsor:   Children's Hospital Los Angeles
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex);   Procedure: Donor peripheral blood stem cell mobiliation and collection;   Procedure: Bone Marrow Harvest Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematological Disease;   Immune Deficiencies;   Solid Tumors;   Myelofibrosis;   Multiple Myeloma;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Drug: Fludarabine;   Drug: Pre-Stem Cell Infusion Cyclophosphamide;   Drug: Pre-Stem Cell Infusion Mesna;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Post-Stem Cell Infusion Cyclophosphamide;   Drug: Post-Stem Cell Infusion Mesna;   Drug: Thiotepa
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
    Sponsor:   University of Rochester
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Biological: GVAX;   Biological: Placebo Vaccine;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Condition:   Bone Marrow Failure Syndromes
    Interventions:   Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Biological: Stem Cell Transplant;   Drug: Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Immunodeficiencies;   Immune Dysregulation Syndromes
    Intervention:   Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
    Sponsors:   Children's Hospital of Philadelphia;   University of California, San Francisco
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplasia
    Intervention:   Device: Alpha Beta T cell depletion
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary T-cell Immunodeficiency Disorders;   Common Variable Immunodeficiency;   Immune System Diseases;   Autoimmune Lymphoproliferative;   Lymphoproliferative Disorders
    Interventions:   Drug: Immunosuppression Only Conditioning;   Drug: Reduced Intensity Conditioning;   Drug: Myeloablative Conditioning;   Drug: GVHD Prophylaxis;   Procedure: Allo BMT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Transfusion Dependent Beta-thalassemia
    Intervention:   Genetic: ST-400 Investigational product
    Sponsors:   Sangamo Therapeutics;   Bioverativ Therapeutics Inc.
    Recruiting

  • Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
    Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Peripheral T-cell Lymphomas;   Lymphoproliferative Disorders;   Immune System Diseases
    Interventions:   Drug: IOC;   Drug: GVHD prophylaxis;   Drug: RIC;   Procedure: allo HCT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Hematological Diseases;   Hemoglobinopathies
    Intervention:   Biological: CTX001
    Sponsors:   Vertex Pharmaceuticals Incorporated;   CRISPR Therapeutics
    Recruiting

  • Condition:   Beta-Thalassemia
    Intervention:   Genetic: LentiGlobin BB305 Drug Product
    Sponsor:   bluebird bio
    Recruiting

  • Condition:   Beta-Thalassemia
    Intervention:   Genetic: LentiGlobin BB305 Drug Product
    Sponsor:   bluebird bio
    Recruiting

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH;   Lurie Children's Hospital of Chicago
    Recruiting

  • Conditions:   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Benign Neoplasm;   Donor
    Interventions:   Drug: Thiotepa;   Drug: Treosulfan;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Rabbit Anti-Thymocyte Globulin;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Genetic: LentiGlobin BB305 Drug Product;   Biological: Plerixafor
    Sponsor:   bluebird bio
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting